Dual antiplatelet therapy may be important for patients who have drug-eluting stents implanted

August 27, 2012

The study, which is being presented at the European Society of Cardiology (ESC) 2012 Annual Congress, examined the effects in the patient of two drug-eluting stents with different healing characteristics (the Endeavor™ zotarolimus-eluting stent, E-ZES, and the Cypher™ sirolimus-eluting stent, C-SES). These scaffold-like medical devices are placed into narrowed arteries to prevent the artery from becoming blocked, and, unlike earlier devices (so-called bare metal stents) which provided purely structural support, are able to slowly release a drug that reduces the cell proliferation, which may otherwise lead to an exuberant scar formation at the site of the stent and narrowing or even occlusion of the vessel.

While drug-eluting stents have been used successfully in millions of patients, evidence suggests that the body sometimes reacts to the stent with local inflammation that increases the risks of delayed healing and the formation of blood clots, a process known as stent thrombosis, which can lead to dangerous adverse events such as myocardial infarction (heart attack).

A team of scientists led by Dr Edoardo Camenzind of the University of Geneva in Switzerland compared the long-term safety of two different types of drug-eluting stent, with different potencies and healing characteristics, the response to the E-ZES being similar to the vascular healing response after bare metal stent implantation. They examined a group of nearly 9000 patients over three years, to determine whether there was any difference in the likelihood of clot formation between the two different types of stent.

According to Dr Camenzind, "Over three years, there seems to be no significant difference in the observed levels of definite or probable stent thrombosis between the two types of stent we tested. However, when we performed a time analysis, this suggested that a difference is emerging over time. Our results seem to suggest that differences are most prominent when use of dual antiplatelet therapy is low, which leads us to postulate that it may prove important for clinicians to ensure that patients who receive stent implants strongly inhibiting cell proliferation also receive an appropriate duration of dual antiplatelet therapy."*

In a linked Comment published alongside the research, Prof. Dr. Jörg Hausleiter and colleagues of the Deutsches Herzzentrum in Munich, add that "Since the study began in 2007, there has been a significant shift in interventional cardiology practice such that both study devices have largely fallen out of use worldwide, being superseded by newer devices with higher efficacy and lower rates of stent thrombosis. Nevertheless, the data remains of interest to physicians caring for the millions of patients already treated with these stents. In addition, the authors have dispelled the misconception that the in-stent tissue growth (thickening of the arteries) associated with less effective drug eluting stents confers lower risk for stent thrombosis."
-end-
NOTES TO EDITORS

* Quotes direct from authors and cannot be found in text of Article / Comment.

Dr Edoardo Camenzind, University of Geneva, Switzerland
T) +41 79 207 9879 E) edoardo@camenzind-cardio.net

Prof. Dr. Jörg Hausleiter, Deutsches Herzzentrum München, Klinik an der Technischen Universität, Munich, Germany
T) +49 89 1218 4018 E) hausleiter@dhm.mhn.de

Lancet

Related Stents Articles from Brightsurf:

3D printed stents that treat inflammation
POSTECH Professor Dong-Woo Cho's research team develops bioink-loaded esophageal stents for treating radiation esophagitis.

Study could be first step in providing personalized care to patients with ureteral stents
Published today in Cell Reports Medicine, researchers at Lawson Health Research Institute and Western University conducted a novel microbiome study to examine bacteria associated with ureteral stents.

Two paths better than one for treating patients with heart stents
Pairing a blood-thinning drug with aspirin daily for patients who have an angioplasty with a stent can contribute to better health outcomes, including lower risk of death, than aspirin alone, according to a recent study by cardiologists at the University of Alberta and Mazankowski Alberta Heart Institute.

Open heart surgery outperforms stents in patients with multivessel disease
Coronary artery bypass grafting (CABG) surgery may be the best treatment option for most patients with more than one blocked heart artery, according to research published today in The Annals of Thoracic Surgery, published by Elsevier.

For infants with heart disease, are shunts or stents better to maintain blood flow?
Infants with various forms of congenital heart disease require a stable source of blood flow to their lungs in order to survive until a more definitive operation can be performed.

3-D-printed polymer stents grow with pediatric patients and biodegrade over time
A new study demonstrates proof-of-concept for combining computational design and simulation tools with 3-D printing technology to produce self-expandable polymer stents that can grow with pediatric patients, are biodegradable, and require only a minimally-invasive procedure for implantation.

Cardiologist warns against dissolvable stents in NEJM
In a New England Journal of Medicine (NEJM) editorial published last week, Debabrata Mukherjee, M.D., provides expert commentary on bioresorbable stents, an alternative to the traditional stents used in patients with cardiac conditions.

A simple fix to avoid some unnecessary coronary stents
Physician researchers at Thomas Jefferson University suspect that some cases of coronary artery spasm go unrecognized and are incorrectly treated with stents.

For malignant biliary obstruction, plastic stents may be cost-effective alternative
Preoperative biliary drainage (PBD) with stent placement has been commonly used for patients with malignant biliary obstruction.

3-D printing customized vascular stents
Using high-resolution 3-D printing, Northwestern University researchers can create flexible, biodegradable stents on-demand that are customized for a patient's specific anatomy.

Read More: Stents News and Stents Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.